FDA Class II Nasal Congestion Device 2026

The U.S. Food and Drug Administration (FDA) issued a final order on November 6, 2026, classifying the external mechanical stimulator for the relief of congestion into Class II with special controls. This action applies to devices that deliver vibrations to the sinus and nasal areas. The classification became effective on the date of the order, though the underlying De Novo decision dates to December 4, 2023.

What Class II Classification Means

Class II devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness, but for which special controls can be established to achieve that assurance. The FDA determined that this classification level is appropriate for the external mechanical stimulator for the relief of congestion. The agency codified the classification under 21 CFR 874.6010.

This step followed a De Novo request submitted by Sound Health Systems, Inc. for its Sonu device. The De Novo process allows the FDA to classify novel postamendments devices into Class I or II when general or special controls can provide reasonable assurance of safety and effectiveness. Once classified, the device can serve as a predicate for future 510(k) submissions.

Special Controls and Risk Mitigation

The final order identifies specific risks associated with this device type and the measures required to address them. Risks include injury from mechanical overstimulation, such as skin irritation, redness, pain, discomfort, headache, vertigo, hearing loss, or tinnitus. Additional risks are adverse tissue reaction and ineffective treatment that could lead to worsening congestion.

Mitigation measures include:

  • Non-clinical performance testing
  • Human factors testing
  • Software verification, validation, and hazard analysis
  • Electrical safety testing
  • Electromagnetic compatibility testing
  • Battery safety testing
  • Labeling
  • Biocompatibility evaluation

Labeling must include details such as frequency range, maximum output power, power source, and an explanation of the user interface. These special controls, combined with general controls, are intended to provide reasonable assurance of safety and effectiveness.

510(k) Premarket Notification Requirement

Devices falling under this classification are subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act. The FDA has not exempted this device type from 510(k) requirements. Manufacturers must demonstrate substantial equivalence to a legally marketed predicate device, supported by the required performance data and compliance with special controls.

Future applicants should evaluate their own device's intended use and technological characteristics against the generic device type definition before relying on this classification.

Oversight Implications

The November 2026 final order is one of several device classifications issued around the same period. Other examples from early November 2026 include Class II classifications for a digital cervical cytology slide imaging system with artificial intelligence algorithm, prognostic assessment software for mild cognitive impairment, and a wearable vibration device for orthopedic use. Each order specifies special controls tailored to the risks of the respective device type.

For the nasal congestion stimulator, the classification reduces regulatory burden compared with automatic Class III assignment while maintaining oversight through special controls and 510(k) review. This approach aligns with the FDA's goal of enhancing patient access to beneficial innovative devices.

Considerations for Consumers

Consumers exploring devices in this category should understand that Class II classification does not imply the absence of risks. The special controls address identified hazards, but individual results may vary. Ineffective use could lead to continued or worsening symptoms.

Anyone considering such a device should review the specific labeling and instructions provided with the product. Human factors testing is required to help ensure users can operate the device correctly based on labeling alone.

Practical Guidance

Before using any new nasal congestion relief device, verify its regulatory status through official FDA resources. Check whether the device has received clearance via the 510(k) process and whether it complies with applicable special controls. Persistent nasal congestion can stem from various underlying causes that may require professional medical evaluation.

Discuss persistent congestion with a qualified healthcare professional and check FDA device information before relying on a new product.

References

Trending

Recommended

Dr. Peter AttiaDr. Peter Attia

Medicare Advantage in Rural Counties for 2027

Medicare Advantage plan availability varies widely by county in 2027. Learn how insurer participation and provider networks may affect choices for older adults in rural US areas, with guidance on comparing options.

18/11/20266 min read
Dr. Peter AttiaDr. Peter Attia

FDA Guidance on IVD Validation for Emerging Pathogens 2026

FDA finalized November 2026 guidance on validating certain IVDs for emerging pathogens during Section 564 emergencies. Learn recommendations for test developers, clinical performance, and analytical validation to support public health readiness.

18/11/20266 min read
Dr. Peter AttiaDr. Peter Attia

CDC Texas HIV Prevention Funding 2026 Changes

Learn about the CDC ending $29.2 million in Texas HIV prevention grants for community organizations. Find what services may be affected and where to access testing and support.

18/11/20266 min read

Share this article: